Shanghai, China, 24 July, 2024 — Recently, the Percutaneous Neuroprotection for Carotid Artery Remodelling (PCAR) Intervention System, jointly developed by MicroPort® NeuroTech™ in collaboration with Prof. Bo Yu's team at Fudan University Pudong Medical Center, achieved a global milestone with the completion of the world's first PCAR procedure at the center.

中国上海，2024年7月24日-最近，MicroPort®NeuroTech™与复旦大学浦东医学中心Bo Yu教授的团队合作开发的颈动脉重塑经皮神经保护（PCAR）干预系统实现了全球里程碑，该中心完成了世界上第一个PCAR程序。

This successful intervention rescued a patient suffering from severe carotid artery stenosis. The PCAR represents an evolution from Transcarotid Artery Revascularization (TCAR), further advancing minimally invasive techniques and simplifying operations..

这项成功的干预措施挽救了一名患有严重颈动脉狭窄的患者。PCAR代表了经颈动脉血运重建（TCAR）的发展，进一步推进了微创技术并简化了操作。。

Carotid artery stenosis is a major cause of ischemic stroke. Clinically, severe stenosis has traditionally been treated through Carotid Endarterectomy (CEA) and Carotid Artery Stenting (CAS). CEA involves surgical removal of the thickened arterial intima and atherosclerotic plaques through an incision in the carotid artery, but it is highly invasive and carries a higher risk of perioperative cardiac events.

颈动脉狭窄是缺血性中风的主要原因。临床上，严重狭窄传统上通过颈动脉内膜切除术（CEA）和颈动脉支架置入术（CAS）进行治疗。CEA涉及通过颈动脉切口手术切除增厚的动脉内膜和动脉粥样硬化斑块，但它具有高度侵袭性，围手术期心脏事件的风险较高。

CAS, while less invasive, involves navigating a tortuous path through the femoral artery to the aortic arch and then to the carotid artery, which can increase the risk of intracranial embolism. To address these challenges, a new intervention method called TCAR was introduced. TCAR involves a small incision in the neck to connect a countercurrent cerebral protection device to the carotid artery and femoral vein, reversing blood flow from the brain through the carotid artery, filtering out dislodged plaques, and returning the blood to the body via the femoral vein.

CAS虽然侵入性较小，但涉及通过股动脉到主动脉弓然后到颈动脉的曲折路径，这可能会增加颅内栓塞的风险。为了应对这些挑战，引入了一种称为TCAR的新干预方法。TCAR涉及颈部的一个小切口，将逆流脑保护装置连接到颈动脉和股静脉，逆转大脑通过颈动脉的血流，过滤掉脱落的斑块，并通过股静脉将血液返回体内。

TCAR has become a mainstream intervention for carotid artery stenosis due to its shorter procedure time, simpler operation, and lower stroke risk..

TCAR由于其手术时间短，操作简单，中风风险低，已成为颈动脉狭窄的主流干预措施。。

Inspired by TCAR, MicroPort® NeuroTech™ and Prof. Bo Yu 's team successfully developed the PCAR system which allows for device placement through a simple puncture, thus making the procedure even less invasive. Moreover, PCAR serves as an important path and adjunct method for the endovascular intervention of cerebrovascular ischemic diseases..

受TCAR的启发，MicroPort®NeuroTech™和Bo Yu教授的团队成功开发了PCAR系统，该系统允许通过简单的穿刺放置设备，从而使该过程的侵入性更小。此外，PCAR是脑血管缺血性疾病血管内介入治疗的重要途径和辅助方法。。

Prof. Bo Yu remarked, 'The successful procedure demonstrates that PCAR can be a vital method for the interventional treatment of cerebrovascular ischemic diseases. PCAR has opened a new pathway for interventional treatment of cerebrovascular diseases and has established a new platform for carotid and cerebrovascular interventions, which allows for further advancements in treatment capabilities, such as intravascular carotid plaque ablation to achieve EndoCEA.'.

Bo Yu教授表示：“成功的手术证明PCAR可以成为介入治疗脑血管缺血性疾病的重要方法。PCAR为脑血管疾病的介入治疗开辟了一条新途径，并为颈动脉和脑血管干预建立了一个新的平台，从而可以进一步提高治疗能力，例如血管内颈动脉斑块消融以实现内分泌。”。

About MicroPort® NeuroTech™

MicroPort® NeuroTech™ (MicroPort NeuroTech Limited; HKEX: 2172) , an associated company of MicroPort® (MicroPort Scientific Corporation; HKEX: 00853), is committed to the research and development of high-end medical devices in the field of neurological interventional treatment with solutions that currently support over 120 cerebrovascular stenting procedures every day.

MicroPort®NeuroTech™（MicroPort NeuroTech Limited；香港交易所：2172）是MicroPort®（MicroPort Scientific Corporation；香港交易所：00853）的关联公司，致力于研究和开发神经介入治疗领域的高端医疗器械，目前每天支持120多种脑血管支架手术。

In the future, MicroPort® NeuroTech™ will continue investing more resources in innovation and development to provide more high-quality and innovative cerebrovascular and neuro intervention solutions for doctors and patients..

未来，MicroPort®NeuroTech™将继续在创新和发展方面投入更多资源，为医生和患者提供更高质量和创新的脑血管和神经干预解决方案。。

More information is available at www.medneurotech.com.

More information is available at www.medneurotech.com.